OUP user menu

CD79a Is Heterogeneously Expressed in Neoplastic and Normal Myeloid Precursors and Megakaryocytes in an Antibody Clone–Dependent Manner

Parul Bhargava MD, Bhaskar V.S. Kallakury MD, Jeffrey S. Ross MD, Norio Azumi MD, PhD, Adam Bagg MD
DOI: http://dx.doi.org/10.1309/UXCDG9PWN7G89Y54 306-313 First published online: 1 August 2007


CD79a, a component of the B-cell antigen receptor complex, can also be expressed in certain non–B-cell malignancies. The reported frequency of CD79a expression in acute myeloid leukemias (AML) ranges from 0% to 90%. We evaluated 39 bone marrow biopsy specimens (29 AML and 10 normal cases) using 5 different commercially available anti-CD79a monoclonal antibody (MoAb) clones. Of 7 acute promyelocytic leukemia (APL) cases, 6 (86%) stained for CD79a with clones HM47/A9 (Novocastra, Newcastle Upon Tyne, England) and HM57 (DAKO, Carpinteria, CA) but were negative with clones 11E3 (Novocastra), and JCB117 (DAKO). Half of 6 acute megakaryoblastic leukemia (AMKL) cases and normal megakaryocytes in 14 (67%) of 21 cases were immunoreactive using clone 11D10 (Novocastra). Approximately one third of non-APL/non-AMKL AML and myeloid precursors in normal marrow specimens stained with clones HM57 and 11D10. This heterogeneity of CD79a expression in AML, megakaryocytes, and myeloid precursors is MoAb clone–dependent, likely owing to different epitope detection, and may be of diagnostic usefulness.

Key Words:
  • CD79a
  • Antibody clones
  • Myeloid
  • Acute promyelocytic leukemia
  • Megakaryocytes
  • Acute megakaryoblastic leukemia
  • AML
  • AML-M3
  • AML-M7